CLIA-Certified vs Direct-to-Consumer Hereditary Cancer Kits

Patients increasingly arrive at the counseling room holding a consumer genetic kit and a question: does this tell me my cancer risk? The honest answer requires unpacking a distinction the packaging works hard to blur — the difference between a direct-to-consumer kit and a CLIA-certified hereditary-cancer panel.

A DTC ancestry kit genotypes common variants to estimate where a person’s ancestors came from. A hereditary-cancer panel interrogates BRCA and other genes for rare, clinically actionable variants under a validated, accredited process. The collection hardware can look identical; the analytic claim is entirely different, and so is what a result means.

CLIA certification is the mechanism that makes a result clinically usable. It ties the reported variant back to a documented, auditable laboratory process with defined performance characteristics. A consumer kit without that chain may genotype accurately and still be unsuitable for a care decision — and a negative ancestry result for a cancer variant is emphatically not a clinical negative.

The practical guidance for patients and the counselors fielding their questions is to evaluate the process, not the box. For a deeper, component-by-component breakdown, see our hardware-first comparison of home genetic testing kits, which compares the two on the hardware and accreditation that actually determine reliability.